MedTrace Logo

Tryptophan as a Modulating Factor in the Antimigraine Efficacy of Triptans

NCT07177885 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 144

Last updated 2026-03-09

No results posted yet for this study

Summary

Migraine is a leading cause of disability, and while triptans are commonly used to treat migraine attacks, over 20% of patients don't respond well to them. This study aims to understand why some people don't benefit from triptans. One key focus is tryptophan, an amino acid that plays a role in migraine and is involved in producing serotonin, which affects pain and inflammation. The study will compare levels of tryptophan and its by-products in patients who respond well to triptans versus those who don't. It will also look at how conditions like inflammatory bowel disease may affect tryptophan absorption. The goal is to improve migraine treatments tailored to different patient needs, though participants may not experience immediate personal benefits.

Conditions

Interventions

BIOLOGICAL

Blood collection

Blood sampling. For patients who have had their cerebrospinal fluid sample taken as part of their treatment, a surplus sample will be used to perform the same measurements.

Sponsors & Collaborators

  • University of the Basque Country (UPV/EHU)

    collaborator OTHER

  • Lariboisière Hospital

    collaborator UNKNOWN

  • University Hospital, Clermont-Ferrand

    lead OTHER

Principal Investigators

  • Xavier Moisset · CHU de Clermont-Ferrand

  • Cristina Alba-Delgado · Université d'Auvergne

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-05
Primary Completion
2028-03-31
Completion
2028-03-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07177885 on ClinicalTrials.gov